{"id":2659,"date":"2026-01-16T12:54:20","date_gmt":"2026-01-16T12:54:20","guid":{"rendered":"https:\/\/finzexpert.com\/blog\/stocks-making-the-biggest-moves-premarket-pnc-ibrx-cpng\/"},"modified":"2026-01-16T12:54:20","modified_gmt":"2026-01-16T12:54:20","slug":"stocks-making-the-biggest-moves-premarket-pnc-ibrx-cpng","status":"publish","type":"post","link":"https:\/\/finzexpert.com\/blog\/stocks-making-the-biggest-moves-premarket-pnc-ibrx-cpng\/","title":{"rendered":"Stocks making the biggest moves premarket: PNC, IBRX, CPNG"},"content":{"rendered":"\n<div>\n<div data-test=\"articleBody-2\" data-analytics=\"RegularArticle-articleBody-5-2\">\n<p><span hidden=\"\" aria-hidden=\"true\" class=\"ArticleBody-extraData\"><span hidden=\"\" aria-hidden=\"true\" class=\"ArticleBody-extraData\"><span hidden=\"\" aria-hidden=\"true\" class=\"xyz-data\">Check out the companies making headlines before the bell. ImmunityBio \u2014 The biotech company rallied 22%, adding to a 30% rally in the previous session that was sparked by strong guidance for its bladder cancer drug Anktiva. ImmunityBio expects full-year revenue for the drug to jump 700%. Coupang \u2014 Shares rose more than 3% after Deutsche Bank upgraded the Korean retail giant to buy, saying most of the regulatory uncertainty has been priced in. QXO \u2014 Shares fell 7% after the roofing products maker announced it would do sell $750 million in common stock. PNC \u2014 The bank rose 3% after posting better-than-expected fourth-quarter results and promising guidance. PNC reported revenue of $5.96 billion versus an LSEG consensus estimate of $5.89 billion. Earnings of $4.88 per share also exceeded a forecast of $4.22 per share. PNC also put its total revenue growth by the end of 2026 at roughly 11%, topping the 8.7% estimated by analysts. \u2014 CNBC&#8217;s Fred Imbert contributed reporting<\/span><\/span><\/span><span class=\"HighlightShare-hidden\" style=\"top:0;left:0\"\/><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Check out the companies making headlines before the bell. ImmunityBio \u2014 The biotech company rallied 22%, adding to a 30% rally in the previous session that was sparked by strong guidance for its bladder cancer drug Anktiva. ImmunityBio expects full-year revenue for the drug to jump 700%. Coupang \u2014 Shares rose more than 3% after [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2660,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8],"tags":[193,2463,2614,192,194,2613,640,191],"class_list":["post-2659","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-loan","tag-biggest","tag-cpng","tag-ibrx","tag-making","tag-moves","tag-pnc","tag-premarket","tag-stocks"],"_links":{"self":[{"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/posts\/2659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/comments?post=2659"}],"version-history":[{"count":0,"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/posts\/2659\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/media\/2660"}],"wp:attachment":[{"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/media?parent=2659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/categories?post=2659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finzexpert.com\/blog\/wp-json\/wp\/v2\/tags?post=2659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}